The global phosphate binders’ market is expected to grow at a significant CAGR during the forecast period (2021-2027). Cardiovascular diseases and diabetes lead to common complications such as nephrology and urology disorders. Unhealthy food habits and drugs are known to cause nephrological and urological diseases. According to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), approximately 26 million people have chronic kidney diseases in the US. The statistics show that about 87,000 patients die due to kidney failure every year. Commonly used drug classes for treating nephrological and urological disorders include diuretics, anti-hypertensive drugs, phosphate binders, and anti-cholinergic and 5-alpha-reductase inhibitors. 

Phosphate binders are drugs that are used to lower the absorption of phosphate in patients suffering from chronic renal failure due to their inability to remove phosphorus naturally. Excess deposition of phosphorus in the body, especially in a kidney failure patient, results in the depletion of calcium from bones and ultimately leads to diseases such as hyperphosphatemia and renal osteodystrophy or renal bone. Phosphate binders work by binding phosphate in the gastrointestinal tract, ultimately making it unavailable to the body for absorption. In June 2014, Keryx Biopharmaceuticals, Inc. received patent for Zerenex, a ferric citrate-based phosphate binder, which will expire in 2024. The company has filed a new drug application (NDA) for Zerenex and is currently under review by the US FDA. Sanofi lost its patent for Renvela (sevelamer) in 2014; the drug generated total revenue of $750 million in 2013. Other key drugs in the market include Alucap (aluminum hydroxide) by Meda Pharma, Calcichew (calcium carbonate), Renagel (sevelamer) by Genzyme Corp., and Fosrenol (lanthanum carbonate) by Shire US, Inc.

The increased frequency of chronic renal disease is propelling the global phosphate binding agents market. Chronic renal disease affects approximately 20 million people in the US, and its prevalence is quickly increasing among adults over the age of 65. The use of these phosphate binding agents in hyperphosphatemia caused by chronic kidney disease has been approved by the FDA. Furthermore, increased awareness of the problems associated with chronic kidney disease and treatment choices is propelling the global phosphate binders market.

Market Coverage

• The market number available for – 2020-2027
• Base year- 2020
• Forecast period- 2021-2027
• Segment Covered
• Regions Covered- Globally

Competitive Landscape: Sanofi S.A., Baxter International Inc., and Opko Health, among others. 

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominates the market in base year?
• Which segment and region will project fastest growth in the market?
• How COVID-19 impacted the market?

o Recovery Timeline

o Deviation from pre-COVID forecast

o Most affected region and segment

• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Phosphate Binders Market Report Segmentation

By Type 

• Calcium-Based Phosphorus Binders,

• Aluminum-Free

• Calcium-Free Phosphorus Binders

• Aluminum-Based Phosphorus Binders

• Magnesium-Based Phosphorus Binders

By Application 

• Hyperphosphatemia

• Hyperphosphatemia Of Renal Failure

• Osteodystrophy

Global Phosphate Binders Market by Region